Psychometric testing of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity (FACT/GOG-Ntx) subscale in a longitudinal study of cancer patients treated with chemotherapy

Hui Lin Cheng; Violeta Lopez; Simon Ching Lam; Anthony Kwun To Leung; Yu Chung Li; Kam Hung Wong; Joseph Siu Kie Au; Raghav Sundar; Alexandre Chan; Terrence Rong De Ng; Lorna Kwai Ping Suen; Choi Wan Chan; Janelle Yorke; Alex Molassiotis

doi:10.1186/s12955-020-01493-y

Psychometric testing of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity (FACT/GOG-Ntx) subscale in a longitudinal study of cancer patients treated with chemotherapy

Hui Lin Cheng
, Violeta Lopez
, Simon Ching Lam
, Anthony Kwun To Leung
, Yu Chung Li
, Kam Hung Wong
, Joseph Siu Kie Au
, Raghav Sundar
, Alexandre Chan
, Terrence Rong De Ng
, Lorna Kwai Ping Suen
, Choi Wan Chan
, Janelle Yorke
, Alex Molassiotis^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

52 Citations (Scopus)

Abstract

Background: The aim of this study was to evaluate the psychometric properties of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity (FACT/GOG-Ntx) subscale in a longitudinal study of cancer patients treated with chemotherapy. Methods: Patients were assessed with the FACT/GOG-Ntx subscale, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chemotherapy-Induced Peripheral Neuropathy Scale 20 (EORTC QLQ-CIPN20), National Cancer Institute -Common Terminology Criteria for Adverse Events (NCI-CTCAE), and light touch test using 10 g monofilament for up to ten assessment points from baseline (prior to initiation of first chemotherapy), after the end of each cycle (up to 6 cycles, 3 weeks per cycle), and at 6, 9, and 12 months after starting chemotherapy. Psychometric analyses included internal consistency reliability, convergent validity, factorial validity, sensitivity to change and responsiveness (minimal clinically important difference, MCID). Results: Cronbach's alpha coefficients of the FACT/GOG-Ntx subscale were 0.82-0.89 across assessment points. The subscale strongly correlated with the EORTC QLQ-CIPN20 (r = 0.79-0.93) but low-to-moderately correlated with the NCI-CTCAE sensory (r s = 0.23-0.45) and motor items (r s = 0.15-0.50) as well as the monofilament test (r s = 0.23-0.47). The hypothesized 4-factor structure of the FACT/GOG-Ntx subscale was not confirmed at assessment points (χ2/df = 2.26-8.50; all P < 0.001). The subscale exhibited small-to-moderate sensitivity to change (r = 0.17-0.37). The MCIDs were between 1.38 and 3.68. Conclusion: The FACT/GOG-Ntx subscale has satisfactory reliability, validity, sensitivity to change and responsiveness to evaluate CIPN in cancer patients. Future research is needed to explore the factorial structure of the FACT/GOG-Ntx subscale as the published four-factor structure was not supported in this study.

Original language	English
Article number	246
Number of pages	9
Journal	Health and Quality of Life Outcomes
Volume	18
Issue number	1
DOIs	https://doi.org/10.1186/s12955-020-01493-y
Publication status	Published - 23 Jul 2020

Bibliographical note

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you giveappropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate ifchanges were made. The images or other third party material in this article are included in the article's Creative Commonslicence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commonslicence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtainpermission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to thedata made available in this article, unless otherwise stated in a credit line to the data.

Data Access Statement

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Funding

The study at the Hong Kong site was funded by the Departmental General Research Funding of School of Nursing in the Hong Kong Polytechnic University.

Keywords

Chemotherapy
Confirmatory factor analysis
EORTC QLQ-CIPN20
FACT/GOG-Ntx
Peripheral neuropathy
Psychometrics
Responsiveness

Access to Document

10.1186/s12955-020-01493-y

Psychometric testing of the Functional Assessment of Cancer Therapy Gynecologic Oncology Group
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you giveappropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate ifchanges were made. The images or other third party material in this article are included in the article's Creative Commonslicence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commonslicence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtainpermission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Final published version, 562 KBLicence: CC BY 4.0

Cite this

Cheng, H. L., Lopez, V., Lam, S. C., Leung, A. K. T., Li, Y. C., Wong, K. H., Au, J. S. K., Sundar, R., Chan, A., De Ng, T. R., Suen, L. K. P., Chan, C. W., Yorke, J., & Molassiotis, A. (2020). Psychometric testing of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity (FACT/GOG-Ntx) subscale in a longitudinal study of cancer patients treated with chemotherapy. Health and Quality of Life Outcomes, 18(1), Article 246. https://doi.org/10.1186/s12955-020-01493-y

@article{3d12f3ff83d640f1b5c43d3f10f702e7,

title = "Psychometric testing of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity (FACT/GOG-Ntx) subscale in a longitudinal study of cancer patients treated with chemotherapy",

abstract = "Background: The aim of this study was to evaluate the psychometric properties of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity (FACT/GOG-Ntx) subscale in a longitudinal study of cancer patients treated with chemotherapy. Methods: Patients were assessed with the FACT/GOG-Ntx subscale, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chemotherapy-Induced Peripheral Neuropathy Scale 20 (EORTC QLQ-CIPN20), National Cancer Institute -Common Terminology Criteria for Adverse Events (NCI-CTCAE), and light touch test using 10 g monofilament for up to ten assessment points from baseline (prior to initiation of first chemotherapy), after the end of each cycle (up to 6 cycles, 3 weeks per cycle), and at 6, 9, and 12 months after starting chemotherapy. Psychometric analyses included internal consistency reliability, convergent validity, factorial validity, sensitivity to change and responsiveness (minimal clinically important difference, MCID). Results: Cronbach's alpha coefficients of the FACT/GOG-Ntx subscale were 0.82-0.89 across assessment points. The subscale strongly correlated with the EORTC QLQ-CIPN20 (r = 0.79-0.93) but low-to-moderately correlated with the NCI-CTCAE sensory (r s = 0.23-0.45) and motor items (r s = 0.15-0.50) as well as the monofilament test (r s = 0.23-0.47). The hypothesized 4-factor structure of the FACT/GOG-Ntx subscale was not confirmed at assessment points (χ2/df = 2.26-8.50; all P < 0.001). The subscale exhibited small-to-moderate sensitivity to change (r = 0.17-0.37). The MCIDs were between 1.38 and 3.68. Conclusion: The FACT/GOG-Ntx subscale has satisfactory reliability, validity, sensitivity to change and responsiveness to evaluate CIPN in cancer patients. Future research is needed to explore the factorial structure of the FACT/GOG-Ntx subscale as the published four-factor structure was not supported in this study.",

keywords = "Chemotherapy, Confirmatory factor analysis, EORTC QLQ-CIPN20, FACT/GOG-Ntx, Peripheral neuropathy, Psychometrics, Responsiveness",

author = "Cheng, \{Hui Lin\} and Violeta Lopez and Lam, \{Simon Ching\} and Leung, \{Anthony Kwun To\} and Li, \{Yu Chung\} and Wong, \{Kam Hung\} and Au, \{Joseph Siu Kie\} and Raghav Sundar and Alexandre Chan and \{De Ng\}, \{Terrence Rong\} and Suen, \{Lorna Kwai Ping\} and Chan, \{Choi Wan\} and Janelle Yorke and Alex Molassiotis",

note = "{\textcopyright} The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you giveappropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate ifchanges were made. The images or other third party material in this article are included in the article's Creative Commonslicence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commonslicence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtainpermission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to thedata made available in this article, unless otherwise stated in a credit line to the data.",

year = "2020",

month = jul,

day = "23",

doi = "10.1186/s12955-020-01493-y",

language = "English",

volume = "18",

journal = "Health and Quality of Life Outcomes",

issn = "1477-7525",

publisher = "BioMed Central",

number = "1",

}

Cheng, HL, Lopez, V, Lam, SC, Leung, AKT, Li, YC, Wong, KH, Au, JSK, Sundar, R, Chan, A, De Ng, TR, Suen, LKP, Chan, CW, Yorke, J & Molassiotis, A 2020, 'Psychometric testing of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity (FACT/GOG-Ntx) subscale in a longitudinal study of cancer patients treated with chemotherapy', Health and Quality of Life Outcomes, vol. 18, no. 1, 246. https://doi.org/10.1186/s12955-020-01493-y

Psychometric testing of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity (FACT/GOG-Ntx) subscale in a longitudinal study of cancer patients treated with chemotherapy. / Cheng, Hui Lin; Lopez, Violeta; Lam, Simon Ching et al.
In: Health and Quality of Life Outcomes, Vol. 18, No. 1, 246, 23.07.2020.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Psychometric testing of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity (FACT/GOG-Ntx) subscale in a longitudinal study of cancer patients treated with chemotherapy

AU - Cheng, Hui Lin

AU - Lopez, Violeta

AU - Lam, Simon Ching

AU - Leung, Anthony Kwun To

AU - Li, Yu Chung

AU - Wong, Kam Hung

AU - Au, Joseph Siu Kie

AU - Sundar, Raghav

AU - Chan, Alexandre

AU - De Ng, Terrence Rong

AU - Suen, Lorna Kwai Ping

AU - Chan, Choi Wan

AU - Yorke, Janelle

AU - Molassiotis, Alex

N1 - © The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you giveappropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate ifchanges were made. The images or other third party material in this article are included in the article's Creative Commonslicence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commonslicence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtainpermission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to thedata made available in this article, unless otherwise stated in a credit line to the data.

PY - 2020/7/23

Y1 - 2020/7/23

N2 - Background: The aim of this study was to evaluate the psychometric properties of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity (FACT/GOG-Ntx) subscale in a longitudinal study of cancer patients treated with chemotherapy. Methods: Patients were assessed with the FACT/GOG-Ntx subscale, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chemotherapy-Induced Peripheral Neuropathy Scale 20 (EORTC QLQ-CIPN20), National Cancer Institute -Common Terminology Criteria for Adverse Events (NCI-CTCAE), and light touch test using 10 g monofilament for up to ten assessment points from baseline (prior to initiation of first chemotherapy), after the end of each cycle (up to 6 cycles, 3 weeks per cycle), and at 6, 9, and 12 months after starting chemotherapy. Psychometric analyses included internal consistency reliability, convergent validity, factorial validity, sensitivity to change and responsiveness (minimal clinically important difference, MCID). Results: Cronbach's alpha coefficients of the FACT/GOG-Ntx subscale were 0.82-0.89 across assessment points. The subscale strongly correlated with the EORTC QLQ-CIPN20 (r = 0.79-0.93) but low-to-moderately correlated with the NCI-CTCAE sensory (r s = 0.23-0.45) and motor items (r s = 0.15-0.50) as well as the monofilament test (r s = 0.23-0.47). The hypothesized 4-factor structure of the FACT/GOG-Ntx subscale was not confirmed at assessment points (χ2/df = 2.26-8.50; all P < 0.001). The subscale exhibited small-to-moderate sensitivity to change (r = 0.17-0.37). The MCIDs were between 1.38 and 3.68. Conclusion: The FACT/GOG-Ntx subscale has satisfactory reliability, validity, sensitivity to change and responsiveness to evaluate CIPN in cancer patients. Future research is needed to explore the factorial structure of the FACT/GOG-Ntx subscale as the published four-factor structure was not supported in this study.

AB - Background: The aim of this study was to evaluate the psychometric properties of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity (FACT/GOG-Ntx) subscale in a longitudinal study of cancer patients treated with chemotherapy. Methods: Patients were assessed with the FACT/GOG-Ntx subscale, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chemotherapy-Induced Peripheral Neuropathy Scale 20 (EORTC QLQ-CIPN20), National Cancer Institute -Common Terminology Criteria for Adverse Events (NCI-CTCAE), and light touch test using 10 g monofilament for up to ten assessment points from baseline (prior to initiation of first chemotherapy), after the end of each cycle (up to 6 cycles, 3 weeks per cycle), and at 6, 9, and 12 months after starting chemotherapy. Psychometric analyses included internal consistency reliability, convergent validity, factorial validity, sensitivity to change and responsiveness (minimal clinically important difference, MCID). Results: Cronbach's alpha coefficients of the FACT/GOG-Ntx subscale were 0.82-0.89 across assessment points. The subscale strongly correlated with the EORTC QLQ-CIPN20 (r = 0.79-0.93) but low-to-moderately correlated with the NCI-CTCAE sensory (r s = 0.23-0.45) and motor items (r s = 0.15-0.50) as well as the monofilament test (r s = 0.23-0.47). The hypothesized 4-factor structure of the FACT/GOG-Ntx subscale was not confirmed at assessment points (χ2/df = 2.26-8.50; all P < 0.001). The subscale exhibited small-to-moderate sensitivity to change (r = 0.17-0.37). The MCIDs were between 1.38 and 3.68. Conclusion: The FACT/GOG-Ntx subscale has satisfactory reliability, validity, sensitivity to change and responsiveness to evaluate CIPN in cancer patients. Future research is needed to explore the factorial structure of the FACT/GOG-Ntx subscale as the published four-factor structure was not supported in this study.

KW - Chemotherapy

KW - Confirmatory factor analysis

KW - EORTC QLQ-CIPN20

KW - FACT/GOG-Ntx

KW - Peripheral neuropathy

KW - Psychometrics

KW - Responsiveness

UR - https://www.scopus.com/pages/publications/85088538008

UR - https://link.springer.com/article/10.1186/s12955-020-01493-y

U2 - 10.1186/s12955-020-01493-y

DO - 10.1186/s12955-020-01493-y

M3 - Article

C2 - 32703223

AN - SCOPUS:85088538008

SN - 1477-7525

VL - 18

JO - Health and Quality of Life Outcomes

JF - Health and Quality of Life Outcomes

IS - 1

M1 - 246

ER -

Psychometric testing of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity (FACT/GOG-Ntx) subscale in a longitudinal study of cancer patients treated with chemotherapy

Abstract

Bibliographical note

Data Access Statement

Funding

Keywords

Access to Document

Other files and links

Fingerprint

Cite this